Drugs | WHO guideline date | Recommendation sentences | Recommend using? | Sentiment orientations (%) | ||
---|---|---|---|---|---|---|
Positive | Negative | Neutral | ||||
Corticosteroids | 2 September 2020 (Version 1) | “A strong recommendation for systemic corticosteroid (severe patients)” “A conditional recommendation against corticosteroid (non-severe patients)” | Yes | 28 (50.00%) | 12 (21.43%) | 16 (28.57%) |
IL-6 | 6 July 2021 (Version 5) | “A strong recommendation to use IL-6 receptor blockers (tocilizumab or sarilumab) in severe or critical patients” | Yes | 48 (50.00%) | 25 (26.04%) | 23 (23.96%) |
HCQ | 17 December 2020 (Version 3) | “A strong recommendation against the use of hydroxychloroquine” | No | 62 (32.63%) | 94 (49.47%) | 34 (17.89%) |
Remdesivir | 20 November 2020 (Version 2) | “A conditional recommendation against the use of remdesivir for patients with COVID-19” | No | 19 (29.23%) | 30 (46.15%) | 16 (24.62%) |
LPV/r | 17 December 2020 (Version 3) | “A strong recommendation against the use of lopinavir/ritonavir” | No | 9 (20.93%) | 25 (58.14%) | 9 (20.93%) |
Ivermectin | 31 March 2021 (Version 4) | “A strong recommendation to use IL-6 receptor blockers (tocilizumab or sarilumab) in severe or critical patients” | No | 4 (30.77%) | 7 (53.85%) | 2 (15.38%) |